Skip to main content
Bio Solution Co.,Ltd. logo

Bio Solution Co.,Ltd. — Investor Relations & Filings

Ticker · 086820 ISIN · KR7086820008 KO Manufacturing
Open in API
Filings indexed 214 across all filing types
Latest filing 2023-11-14 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 086820

About Bio Solution Co.,Ltd.

https://bio-solution.co.kr/

Bio Solution Co., Ltd. is a biotechnology company focused on the development, manufacturing, and sale of cell therapy products. The company's core activities involve cell-based biotechnology, producing therapeutics such as autologous chondrocyte treatments for cartilage regeneration. In addition to its therapeutic offerings, Bio Solution develops human tissue models and provides alternative testing solutions. The company also manufactures and distributes a portfolio of bio-laboratory products, including ready-to-use kits, staining solutions, and various reagents for molecular biology research and development applications.

Recent filings

Filing Released Lang Actions
분기보고서 (2023.09)
Interim / Quarterly Report Classification · 1% confidence The document is a '분기보고서' (Quarterly Report) for the company '주식회사 바이오솔루션' (Bio Solution Co., Ltd.) covering the period from January 1, 2023, to September 30, 2023. It contains detailed financial statements, management discussion and analysis, and corporate governance information, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2023
2023-11-14 Korean
소송등의제기ㆍ신청(경영권분쟁소송)(주주명부열람등사)
Legal Proceedings Report Classification · 1% confidence The document is a formal regulatory disclosure regarding a legal proceeding ('소송 등의 제기ㆍ신청') involving a management dispute ('경영권 분쟁 소송') and a request for shareholder register inspection ('주주명부열람등사'). Since it details a specific legal action/lawsuit filed against the company, it falls under the 'Legal Proceedings Report' category.
2023-08-24 Korean
투자판단관련주요경영사항(임상시험계획승인신청)(펠렛형 동종 연골세포치료제(카티로이드)의 제1/2상 임상시험계획승인 신청)
Regulatory Filings Classification · 1% confidence The document is a regulatory filing from a Korean company (BioSolution) announcing the submission of an Investigational New Drug (IND) application for a clinical trial. It details the clinical trial phase, purpose, and regulatory submission date. Since it is a specific regulatory announcement regarding clinical trial status and does not fit into categories like financial reports or shareholder meetings, it is classified as a general regulatory filing.
2023-08-14 Korean
반기보고서 (2023.06)
Interim / Quarterly Report Classification · 1% confidence The document is a '반기보고서' (Semi-Annual Report) for the company '주식회사 바이오솔루션' covering the period from 2023-01-01 to 2023-06-30. It contains detailed financial statements, management discussion, and business operations information, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2023
2023-08-14 Korean
분기보고서 (2023.03)
Interim / Quarterly Report Classification · 1% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'Bio Solution Co., Ltd.' covering the period from January 1, 2023, to March 31, 2023. It contains detailed financial statements, management discussion and analysis, and corporate governance information, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2023
2023-05-15 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act (Article 147). It details changes in share ownership by major shareholders and their special relations, including specific transaction dates, volumes, and purposes. This type of filing is categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2023-04-11 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.